



FOR RELEASE on September 25<sup>th</sup>, 2025

# ALCEDIAG, OM Pharma Suisse and Unilabs Announce Swiss Launch of EDIT-B<sup>®</sup>, the World's First Blood Test to Help Differentiate Depression and Bipolar Disorder.

Geneva and Paris — September 25<sup>th</sup>, 2025

ALCEDIAG, OM Pharma Suisse, and Unilabs today announced the launch of **EDIT-B<sup>®</sup>**, the **world's first CE-marked and Swissmedic compliant blood test designed to differentiate depression and bipolar disorder**, now available nationwide in clinical routine in Switzerland and Liechtenstein. This innovative diagnostic solution, a breakthrough in mental health diagnostics, will be accessible to clinicians and patients, addressing a critical unmet medical need in mental healthcare.

**Bipolar disorder (BD)** is a major public health concern, affecting approximately **80,000 people in Switzerland**. One of the most critical challenges is the **long diagnostic delay** - averaging **8 years** between the onset of symptoms and an accurate diagnosis. This delay is primarily because BD and depression show significantly overlapping symptoms and are therefore often confused, leading to misdiagnosed patients receiving inappropriate treatment that may even worsen their health condition. The current practice for diagnosing BD relies on psychiatric clinical examination.

EDIT-B<sup>®</sup>'s objective is to help clinicians reach a quicker diagnosis, by offering **high performance, validated and rapid biological answer** to significantly reduce the diagnostic uncertainty and delay between depression and BD. Available by prescription only, the test is intended for adult patients presenting with a moderate to severe major depressive episode and under treatment.

This launch is made possible through the productive collaboration of three key partners:

- **ALCEDIAG**, the biotechnology company behind the test EDIT-B<sup>®</sup> and a pioneer in RNA biomarkers in precision psychiatry, developed the test and ensured its regulatory compliance using state-of-the-art Next Generation Sequencing (NGS) technology coupled with proprietary AI algorithms. Alexandra Prioux, CEO of Alcediag, says: "The introduction of EDIT-B<sup>®</sup> in Switzerland marks an important milestone in our mission to advance innovation and precision psychiatry. We are happy to collaborate with OM Pharma and Unilabs, whose talented teams are as committed as we are to the wellbeing of patients".



- **OM Pharma** Suisse will promote and support medical education around the test in Switzerland. Dr. Daniele Andreutti, General Manager of OM Pharma Suisse, stated, “OM Pharma Suisse is proud to support the launch of EDIT-B® in Switzerland. This test demonstrates how science and technology can transform patient care in psychiatry and help bring a faster diagnosis to the patients.”
- **Unilabs** will serve as the central laboratory, providing EDIT-B® to clinicians and their patients across the country, ensuring broad clinical access. Dr. Dany Mercan, Head of Medical of Unilabs Switzerland, notes, “Unilabs is proud to bring EDIT-B® to clinicians across Switzerland. With our strong expertise in molecular diagnostics and a nationwide footprint of 18 labs, 24 blood collection centers, numerous partners and flying nurses, we’re ensuring broad access to this landmark breakthrough in psychiatric diagnostics and improving care for patients facing mental health challenges.”

To mark the Swiss launch, OM Pharma Suisse organized a dedicated symposium on EDIT-B® on the occasion of the Swiss Annual Psychiatry Conference (SGPP), that took place in Basel on Sept 18, 2025. The event featured leading experts and provided an opportunity for Swiss psychiatrists to learn more about the test and its integration into clinical practice.

#### **About EDIT-B®**

EDIT-B® is a first-in-class, CE-marked and **compliant with the Swiss In Vitro Diagnostic Medical Devices Ordinance (IvDO)** blood test, clinically validated to demonstrate high sensitivity and specificity (exceeding 80%) for the differential diagnosis of bipolar disorder and depression.

The EDIT-B® biological test complements existing clinical data and scales, positioning itself as a key decision-making support tool for prescribing mental healthcare providers.

EDIT-B® seamlessly integrates into the clinical workflow. Its primary goal is to empower clinicians to facilitate the prompt selection of appropriate therapeutic treatments and to aid patients in leading improved lives by shortening the typical delays associated with diagnosis, from an average of 8 years to a matter of mere weeks.

#### **About ALCEDIAG**

Founded in 2013, ALCEDIAG is a pioneering diagnostics company dedicated to transforming mental health through precision psychiatry. The company develops and commercializes innovative in-vitro diagnostic tests powered by cutting-edge molecular biology and artificial intelligence. Its proprietary platform leverages RNA editing based biomarkers to bring objective, science-based tools into clinical psychiatric practice.

#### **About OM Pharma Suisse**



---

ALCEDIAG

---

PH HEALTH



OM Pharma Suisse is the Swiss affiliate of OM Pharma, and an expert in the marketing and commercialisation of a diverse portfolio which includes more than 30 pharmaceutical products including in the field of mental health in Switzerland.

### **About Unilabs**

Unilabs Switzerland is a leading provider of integrated diagnostic services, combining Laboratory Medicine, Radiology, Pathology and Genetics to support clinicians in delivering timely and accurate care. As part of a pan-European network, Unilabs is committed to innovation, quality, and patient-centered service, helping shape the future of precision medicine.

### **Media Contacts**

[communication@ompharma.com](mailto:communication@ompharma.com) – Contact person: Mrs. Sandrine Moncere